| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
ER
The primary targets are estrogen receptor α (ERα) and estrogen receptor β (ERβ); estradiol hemihydrate binds ERα with high affinity (IC50 = 3.6 nM in competitive binding assays) and activates estrogen-responsive gene transcription. It also modulates membrane-associated estrogen signaling, upregulates neural markers in human endometrial stem cells, and promotes neural differentiation. |
|---|---|
| ln Vitro |
Human endometrial stem cells (hEnSC) are exposed to estradiol hemihydrate (10 nM) for seven days, during which time it promotes neurite branching and neural development [1]. In hEnSC-differentiated neuronal-like cells, estradiol hemihydrate (17β-estradiol, 10 nM, 7 days) enhances the expression of neuron-like cell markers (Tuj-1, nestin, and NF-H) [1]. Assay for cell differentiation [1]
Estradiol hemihydrate binds ERα with IC50 = 3.6 nM and activates ER-mediated transcriptional activity in reporter assays; it upregulates neural markers (e.g., BDNF, synaptophysin, PSD95) in human endometrial stem cells (hEnSCs) and facilitates their neural differentiation, and it modulates estrogen-responsive gene expression in breast and endometrial cancer cell lines with potency in the nanomolar range. |
| ln Vivo |
Estradiol hemihydrate (1 nM, hippocampal slices from FBN-ARO-KO mice) recovers long-term potentiation (LTP) amplitude [1]. Estradiol hemihydrate (0.0167 mg, subcutaneously implanted in FBN-ARO-KO mice) cures molecular and functional abnormalities in FBN-ARO-KO animals [1].
In vivo, estradiol hemihydrate restores BDNF levels to 80–90% and both synaptophysin and PSD95 in the forebrain of ovariectomized rodents; it promotes neural differentiation and tissue repair, maintains reproductive-tract trophism, and is used in menopausal hormone therapy and in animal models of menopause, neurodegeneration, and hormone-dependent cancers. |
| Enzyme Assay |
Estrogen receptor binding is measured using recombinant ERα or ERβ ligand-binding domain and a fluorescent or radiolabeled estradiol competitor (e.g., [3H]estradiol or Fluormone ES2); graded estradiol hemihydrate concentrations displace the probe, and IC50 or Ki values are calculated from dose–response curves. Selectivity is assessed against ERβ and other nuclear receptors.
|
| Cell Assay |
Cell differentiation assay[1]
Cell Types: Human endometrial stem cells (hEnSC) isolated from human endometrial tissue Tested Concentrations: 10 nM Incubation Duration: 7 days Experimental Results: Neural markers (Tuj-1, Nestin and NF The percentage increases of -H)-positive cells were 62.2±1.3%, 71.5±4% and 51.2±1.5%, respectively. Immunofluorescence[1] Cell Types: Human endometrial stem cells (hEnSC) isolated from human endometrial tissue Tested Concentrations: 10 nM Incubation Duration: 7 days Experimental Results: Neural markers (Tuj-1, Nestin and NF- H) The percentage increases of positive cells were 62.2±1.3%, 71.5±4% and 51.2±1.5% respectively. ER-positive breast cancer cells (MCF-7, T47D) or human endometrial stem cells are treated with estradiol hemihydrate (0.01–100 nM) for 24–72 h; ER-mediated transcription is measured by luciferase reporter assay, proliferation by thymidine incorporation or metabolic assays, ER target gene expression (e.g., progesterone receptor, pS2) by RT-qPCR, and neural differentiation markers by Western blotting and immunofluorescence. |
| Animal Protocol |
Animal/Disease Models: FBN-ARO-KO mice [2]
Doses: 1 nM Route of Administration: Treatment of hippocampal slices Experimental Results: Long-term potentiation (LTP) amplitude was restored in both male and female mice. Animal/Disease Models: FBN-ARO-KO mice [2] Doses: 0.0167 mg Route of Administration: Alzet minipump containing estradiol (subcutaneously (sc) (sc) implanted) was used, and examinations were performed 7 days after minipump implantation. Experimental Results: E2 levels in the hippocampus and cortex were restored to 93%, AKT, ERK and CREB phosphorylation in the hippocampus and cortex were restored to 90-95%, BDNF levels were restored to 80-90%, and forebrain synaptophysin and PSD95 were restored. Rescues spatial learning and memory deficits. Ovariectomized rats or mice receive estradiol hemihydrate by subcutaneous or oral administration at doses selected from pharmacokinetic studies (e.g., 0.1–10 µg/kg/day); uterine weight and vaginal cytology are measured as estrogenic endpoints, brain tissue is analyzed for BDNF, synaptophysin, and PSD95 by Western blotting or immunohistochemistry, and plasma estradiol concentrations are quantified to correlate receptor occupancy with neurotrophic and peripheral effects. |
| References | |
| Additional Infomation |
Estradiol hemihydrate is the hemihydrate form of estradiol, the most potent natural estrogen in the body. Estradiol hemihydrate diffuses across cell membranes and binds to nuclear estrogen receptors located in the reproductive tract, mammary glands, pituitary gland, hypothalamus, liver, and bones, thereby activating these receptors. The activated complex binds to estrogen-responsive elements on DNA, activating the transcription of genes involved in female reproductive system function and secondary sexual characteristic development. The 17β-isomer of estradiol is an aromatic C18 steroid with hydroxyl groups at both the 3β and 17β positions. Estradiol 17β is the most potent estrogenic steroid in mammals. See also: Estradiol (including the active moiety)... See more...
|
| Molecular Formula |
2[C18H24O2].H2O
|
|---|---|
| Molecular Weight |
281.39
|
| Exact Mass |
562.365
|
| CAS # |
35380-71-3
|
| Related CAS # |
Alpha-Estradiol;57-91-0;Estradiol (Standard);50-28-2;Estradiol-d3;79037-37-9;Estradiol-d4;66789-03-5;Estradiol-d5;221093-45-4;Estradiol-13C2;82938-05-4;Estradiol (cypionate);313-06-4;Estradiol benzoate;50-50-0;Estradiol enanthate;4956-37-0;Estradiol hemihydrate;35380-71-3;Estradiol-d2;53866-33-4;Estradiol-13C6;Estradiol-d2-1;3188-46-3;rel-Estradiol-13C6; 979-32-8 (valerate); 113-38-2 (dipropionate); 57-63-6 (ethinyl); 172377-52-5 (sulfamate); 3571-53-7 (undecylate)
|
| PubChem CID |
154274
|
| Appearance |
White to off-white solid
|
| Boiling Point |
445.9ºC at 760mmHg
|
| Flash Point |
209.6ºC
|
| Source |
Endogenously produced metabolite
|
| LogP |
3.544
|
| tPSA |
49.69
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
41
|
| Complexity |
382
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
O.OC1C=CC2[C@H]3CC[C@@]4([C@H](CC[C@H]4[C@@H]3CCC=2C=1)O)C.OC1C=CC2[C@H]3CC[C@@]4([C@H](CC[C@H]4[C@@H]3CCC=2C=1)O)C
|
| InChi Key |
ZVVGLAMWAQMPDR-WVEWYJOQSA-N
|
| InChi Code |
InChI=1S/2C18H24O2.H2O/c2*1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20;/h2*3,5,10,14-17,19-20H,2,4,6-9H2,1H3;1H2/t2*14-,15-,16+,17+,18+;/m11./s1
|
| Chemical Name |
(8R,9S,13S,14S,17S)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol;hydrate
|
| Synonyms |
ESTRADIOL HEMIHYDRATE; 35380-71-3; beta-Estradiol semihydrate; UNII-CXY7B3Q98Z; CXY7B3Q98Z; Estra-1,3,5(10)-triene-3,17beta-diol hydrate (2:1); beta-Estradiol hemihydrate; Estrasorb (TN);
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ≥ 100 mg/mL (~355.4 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.88 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5538 mL | 17.7689 mL | 35.5379 mL | |
| 5 mM | 0.7108 mL | 3.5538 mL | 7.1076 mL | |
| 10 mM | 0.3554 mL | 1.7769 mL | 3.5538 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.